Furthermore, PROX1, EZH2 and SIRT3 expression are potentially useful prognostic biomarkers in CRC, and targeting the PROX1-EZH2-SIRT3 axis might present a novel therapeutic strategy for CRC. The gene discussed is EZH2; the disease is colorectal carcinoma.